Q4 2025 Milestone Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Milestone Pharmaceuticals Inc (MIST) received FDA approval for CARDAMYST, a nasal spray for paroxysmal supraventricular tachycardia (PSVT), marking a significant milestone for the company.
- The company successfully launched CARDAMYST in the market within six weeks of FDA approval, demonstrating efficient execution.
- Milestone Pharmaceuticals Inc (MIST) is well-capitalized with a pro forma cash figure of approximately $200 million, providing an operating runway into late 2027.
- The company has engaged with the European Medicines Agency (EMA) for marketing approval in Europe, indicating potential international expansion.
- Initial feedback from prescribers regarding CARDAMYST has been positive, with over 150 prescriptions filled by more than 100 unique prescribers in the first month of launch.
- Milestone Pharmaceuticals Inc (MIST) faces challenges with insurance coverage, as many prescriptions are delayed or blocked due to insurer controls.
- The company reported a net loss of $63.1 million for the full year 2025, an increase from the previous year.
- There is a natural dampening effect on prescription fills due to the lack of contracted coverage, with more than half of scripts not getting through.
- The company is still in the early stages of launch, making it difficult to identify durable trends or patterns in CARDAMYST's market performance.
- Milestone Pharmaceuticals Inc (MIST) anticipates that Medicare coverage will take longer to achieve, with expectations set for 2027.
Good morning, ladies and gentlemen, and welcome to the Milestone Pharmaceuticals fourth quarter and year-end 2025 corporate update conference call. (Operator Instructions)
As a reminder, this conference is being recorded. I will now turn the call over to your host, Michael Wood of LifeSci Advisors. You may now begin your conference.
Thank you, operator. Good morning, everyone, and welcome to the Milestone Pharmaceuticals full year 2025 financial results and business update conference call. Earlier this morning, the company issued a press release providing an overview of its financial results for the year ended December 31, 2025, and recent corporate highlights. The release can be accessed on the Investors Media section of the company's website, milestone pharma.com.
Before I begin, I'd like to remind everyone that some of the information presented on this conference call contains forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
